scholarly journals Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes

2012 ◽  
Vol 97 (12) ◽  
pp. 4701-4708 ◽  
Author(s):  
Kwok Leung Ong ◽  
Kerry-Anne Rye ◽  
Rachel O'Connell ◽  
Alicia J. Jenkins ◽  
Chris Brown ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Retinol Binding Protein 4

Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes

2016 ◽  
Vol 18 (3) ◽  
pp. 120-126 ◽  
Author(s):  
Hui Fan ◽  
XiaoMeng Sun ◽  
Heng Zhang ◽  
Jia Liu ◽  
PengRui Zhang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Newly Diagnosed

scholarly journals High Plasma Level of Fibroblast Growth Factor 21 Is an Independent Predictor of Type 2 Diabetes: Table 1

Diabetes Care ◽  
2011 ◽  
Vol 34 (9) ◽  
pp. 2113-2115 ◽  
Author(s):  
Cheng Chen ◽  
Bernard M.Y. Cheung ◽  
Annette W.K. Tso ◽  
Yudong Wang ◽  
Lawrence S.C. Law ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Growth Factor ◽  
Plasma Level ◽  
Fibroblast Growth Factor ◽  
Independent Predictor ◽  
High Plasma ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
High Plasma Level

scholarly journals Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus

2009 ◽  
Vol 161 (3) ◽  
pp. 391-395 ◽  
Author(s):  
Ke Li ◽  
Ling Li ◽  
Mengliu Yang ◽  
Haihong Zong ◽  
Hua Liu ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 21 ◽  
Diabetic Patients ◽  
Fibroblast Growth ◽  
Fasting Plasma

ObjectiveFibroblast growth factor-21 (FGF-21) has recently been characterized as a potent metabolic regulator, but its pathophysiologic roles in humans remain unknown. This study aimed to investigate the effects of rosiglitazone on plasma FGF-21 levels in patients with type 2 diabetes mellitus (T2DM).Design and methodsThirty patients with new-onset T2DM (nT2DM), 34 type 2 diabetic patients with poor glycemic control (pT2DM) after the treatment with single hypoglycemic agent metformin, and 30 sex- and age-matched normal glycaemic controls (NGT) participated in the study. The pT2DM group was treated with rosiglitazone for 12 weeks. Plasma FGF-21 levels were measured with a RIA. The relationship between plasma FGF-21 levels and metabolic parameters was also analyzed.ResultsFasting plasma FGF-21 levels were higher in nT2DM and pT2DM groups than in the control (1.81±0.64 vs 1.87±0.63 vs 1.52±0.61 μg/l, P<0.05), but there was no difference between nT2DM and pT2DM groups. Fasting plasma FGF-21 levels were decreased significantly in pT2DM group after the treatment with rosiglitazone compared with pre-treatment (1.59±0.63 vs 1.87±0.64 μ/l, P<0.05). In all diabetic patients, multiple regression analysis showed that HbA1c, fasting insulin, and homeostasis model assessment-insulin resistance index were independently associated with plasma FGF-21 levels.ConclusionsIn pT2DM patients, plasma FGF-21 levels are increased, but significantly decreased after the treatment with rosiglitazone on top of ongoing metformin therapy. These data suggest that rosiglitazone may play a role in lowering FGF-21 levels in T2DM patients.

Sign in / Sign up

Export Citation Format

Share Document